[
    [
        {
            "time": "2023-08-31",
            "original_text": "泰格医药(03347)8月31日斥3亿元首次回购223.89万股A股股份",
            "features": {
                "keywords": [
                    "泰格医药",
                    "回购",
                    "股份",
                    "3亿元",
                    "223.89万股"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药(03347)8月31日斥3亿元首次回购223.89万股A股股份",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-09-01",
            "original_text": "泰格医药：8月31日、9月1日合计耗资3.12亿元回购233.25万股A股股份",
            "features": {
                "keywords": [
                    "泰格医药",
                    "回购",
                    "股份",
                    "3.12亿元",
                    "233.25万股"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药：8月31日、9月1日合计耗资3.12亿元回购233.25万股A股股份",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-09-01",
            "original_text": "泰格医药(300347.SZ)：8月31日首次回购223.89万股A股",
            "features": {
                "keywords": [
                    "泰格医药",
                    "首次回购",
                    "223.89万股"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药(300347.SZ)：8月31日首次回购223.89万股A股",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-09-01",
            "original_text": "天风证券维持泰格医药买入评级：业绩强劲增长，在手订单持续放量",
            "features": {
                "keywords": [
                    "天风证券",
                    "泰格医药",
                    "买入评级",
                    "业绩增长",
                    "订单放量"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天风证券维持泰格医药买入评级：业绩强劲增长，在手订单持续放量",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-09-01",
            "original_text": "医药生物行业周报：医美行业强化监管 安徽省IVD集采结果公布",
            "features": {
                "keywords": [
                    "医药生物",
                    "医美行业",
                    "强化监管",
                    "安徽省",
                    "IVD集采"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药生物行业周报：医美行业强化监管 安徽省IVD集采结果公布",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-09-01",
            "original_text": "医药与健康护理行业月报：智飞生物新冠疫苗III期数据优异 对变异株仍然有效",
            "features": {
                "keywords": [
                    "医药",
                    "智飞生物",
                    "新冠疫苗",
                    "III期数据",
                    "变异株"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药与健康护理行业月报：智飞生物新冠疫苗III期数据优异 对变异株仍然有效",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]